Please harness analysis of HLS Therapeutics fundamentals to determine if markets are correctly pricing the company. We are able to interpolate and collect thirty-four available reported financial drivers for HLS Therapeutics, which can be compared to its competitors. The stock experiences a normal downward trend and little activity. Check odds of HLS Therapeutics to be traded at C$3.47 in 90 days. Key indicators impacting HLS Therapeutics' financial strength include:
Understanding current and past HLS Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of HLS Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in HLS Therapeutics' assets may result in an increase in income on the income statement.
HLS Therapeutics competes with Profound Medical, Medicenna Therapeutics, Knight Therapeutics, and Aptose Biosciences. HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It has license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. HLS THERAPEUTICS operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on Toronto Stock Exchange. It employs 46 people.
Foreign Associate
USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
You should never invest in HLS Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of HLS Stock, because this is throwing your money away. Analyzing the key information contained in HLS Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
HLS Therapeutics Key Financial Ratios
HLS Therapeutics' financial ratios allow both analysts and investors to convert raw data from HLS Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of HLS Therapeutics over time and compare it to other companies across industries.
Comparative valuation techniques use various fundamental indicators to help in determining HLS Therapeutics's current stock value. Our valuation model uses many indicators to compare HLS Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HLS Therapeutics competition to find correlations between indicators driving HLS Therapeutics's intrinsic value. More Info.
HLS Therapeutics is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . At this time, HLS Therapeutics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value HLS Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for HLS Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.
HLS Therapeutics Systematic Risk
HLS Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. HLS Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on HLS Therapeutics correlated with the market. If Beta is less than 0 HLS Therapeutics generally moves in the opposite direction as compared to the market. If HLS Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one HLS Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of HLS Therapeutics is generally in the same direction as the market. If Beta > 1 HLS Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
HLS Therapeutics Total Assets Over Time
Today, most investors in HLS Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various HLS Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of HLS Therapeutics growth as a starting point in their analysis.
HLS Therapeutics December 4, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of HLS Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of HLS Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of HLS Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing HLS Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build HLS Therapeutics's daily price indicators and compare them against related drivers.
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.